Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 185

The DOI matches its Crossref record.

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

Open access
Shelton, Edward, Allegretti, Jessica R., Stevens, Betsy, Lucci, Matthew, Khalili, Hamed, Nguyen, Deanna D., Sauk, Jenny, Giallourakis, Cosmas, Garber, John, Hamilton, Matthew J., Tomczak, Michal, Makrauer, Fredrick, Burakoff, Robert B., Levine, Jonathan, de Silva, Punyaganie, Friedman, Sonia, Ananthakrishnan, Ashwin, Korzenik, Joshua R., Yajnik, Vijay · 2015 · Inflammatory Bowel Diseases

Abstract

BACKGROUND: Vedolizumab (VDZ) demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of VDZ at week 14 in inflammatory bowel disease in a multicenter cohort of patients. METHODS: Patients at Massachusetts General Hospital and Brigham and Women's Hospital were considered for inclusion. VDZ (300 mg) was administered at weeks 0, 2, 6, and 14. Efficacy was assessed using the Harvey-Bradshaw index for CD, the simple clinical colitis activity index for UC and physician assessment, along with C-reactive protein and decrease of corticosteroid therapy. Clinical response was defined as decrease in Harvey-Bradshaw index ≥3 and simple clinical colitis activity index ≥3 and remission as Harvey-Bradshaw index ≤4, simple clinical colitis activity index ≤2 and physician assessment of response and remission. RESULTS: Our study included 172 patients (107 CD, 59 UC, 6 inflammatory bowel disease-unclassified, men 48.3%, mean age 40 years and disease duration 14 years). Fourteen patients had ostomy and 9 ileoanal pouch, and only 35.5% fulfilled eligibility for the GEMINI trials. Previous treatment failures with ≥ 2 anti-TNFs occurred in 70.9%, one-third were on an immunomodulator and 46% systemic steroids at baseline. In CD, 48.9% and 23.9% and in UC, 53.9% and 29.3% had clinical response and clinical remission at week 14, respectively. Adverse events occurred in 10.5%. CONCLUSIONS: VDZ is safe and well tolerated in refractory inflammatory bowel disease patients in a clinical practice with efficacy in UC and CD with responses similar to what was seen in clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0000000000000561

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 185

Metadata

Authors
Shelton, E., Allegretti, J. R., Stevens, B., Lucci, M., Khalili, H., Nguyen, D. D., Sauk, J., Giallourakis, C., Garber, J., Hamilton, M. J., Tomczak, M., Makrauer, F., Burakoff, R. B., Levine, J., de Silva, P., Friedman, S., Ananthakrishnan, A., Korzenik, J. R., & Yajnik, V.
Venue
Inflammatory Bowel Diseases
Published
2015-12
Volume
21
Issue
12
Pages
2879-2885
ISSN
1078-0998 (ISSN-L)
OpenAlex
W1147871078
Cited by
185
References
0
FWCI
17.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. https://app.cochat.ai/papers/10.1097/mib.0000000000000561
The paper
Shelton, E., Allegretti, J. R., Stevens, B., Lucci, M., Khalili, H., Nguyen, D. D., Sauk, J., Giallourakis, C., Garber, J., Hamilton, M. J., Tomczak, M., Makrauer, F., Burakoff, R. B., Levine, J., de Silva, P., Friedman, S., Ananthakrishnan, A., Korzenik, J. R., & Yajnik, V. (2015). Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000561

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.